Overview of the drug development pipeline for graves’ disease
Graves’ disease is an autoimmune disorder that causes the thyroid gland to produce excess thyroid hormone in the body. Factors such as inheritance from either parent or any other autoimmune disorders are consequent in the occurrence of this disease. Also, unknown infection or emotional/physical stress increase the incidence of graves’ disease. This disorder gives rise to symptoms such as Goitre, weight loss, frequent bowel movements, trouble getting pregnant, and hair thinning. Technavio’s market research analysts outlines that this disorder can be treated with therapeutics such as medication, radioiodine therapy, and thyroid surgery. Companies in the pharmaceutical industry are investing steadily in drug development activities.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the discovery drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the phase I/II and pre-clinical drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I stage.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of graves’ disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- Novartis
- Evofem Biosciences
- Thyritope Biosciences
Therapeutic assessment of the drug development pipeline for graves’ disease by route of administration
- Intradermal
- Intramuscular
- Intravenous
The intradermal route of administration (ROA) involves the administration of drug substances within the layers of the skin. It has been observed that the two of total therapeutics for graves’ diseases are being developed for intradermal administration.
Therapeutic assessment of the drug development pipeline for graves’ disease by therapeutic modality
- Peptide
- Monoclonal antibody
- Small molecule
According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for graves’ disease are being developed as peptides. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. The reaction of carboxyl group of one amino acid with another amino acid group is consequent in the formation of covalent chemical bonds.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX